17) Rapoport BL, Weinstein C, Camacho ES, et al. A phase 3, randomized, double—blind study
of single—dose intravenous fosaprepitant in preventing chemotherapy—induced nausea
and vomiting associated with moderately emetogenic chemotherapy. J Clin Oncol. 2015;
33(supple; abstr 9629).
(Ⅱ)
40